Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 35Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 3Aprovel

02 5Cozaar/Hyzaar

03 1Diovan

04 5Diovan Group

05 2Diovan/Co-Diovan

PharmaCompass

01

Brand Name : Aprovel

arrow
Medlab Asia & Asia Health
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Hydrochlorothiazide

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2019 Revenue in Millions : 735

2018 Revenue in Millions : 711

Growth (%) : 3

Sanofi Company Banner

02

Brand Name : Aprovel

arrow
Medlab Asia & Asia Health
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Hydrochlorothiazide

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 670

2019 Revenue in Millions : 815

Growth (%) : -18

Sanofi Company Banner

03

Brand Name : Aprovel

arrow
Medlab Asia & Asia Health
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Hydrochlorothiazide

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 461

2020 Revenue in Millions : 604

Growth (%) : -24

Sanofi Company Banner

04

Brand Name : Cozaar/Hyzaar

Hydrochlorothiazide

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Cozaar/Hyzaar

arrow
Medlab Asia & Asia Health
Not Confirmed

Hydrochlorothiazide

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 386

2019 Revenue in Millions : 442

Growth (%) : -13

blank

05

Brand Name : Diovan Group

Hydrochlorothiazide

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Diovan Group

arrow
Medlab Asia & Asia Health
Not Confirmed

Hydrochlorothiazide

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 1,003

2019 Revenue in Millions : 1,064

Growth (%) : -6

blank

06

Brand Name : Cozaar/Hyzaar

Potassium Hydrochlorothiazide

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Cozaar/Hyzaar

arrow
Medlab Asia & Asia Health
Not Confirmed

Potassium Hydrochlorothiazide

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 357

2020 Revenue in Millions : 386

Growth (%) : -8

blank

07

Brand Name : Diovan Group

Hydrochlorothiazide

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Diovan Group

arrow
Medlab Asia & Asia Health
Not Confirmed

Hydrochlorothiazide

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 773

2020 Revenue in Millions : 1,003

Growth (%) : -23

blank

08

Brand Name : Diovan Group

Hydrochlorothiazide

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Diovan Group

arrow
Medlab Asia & Asia Health
Not Confirmed

Hydrochlorothiazide

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 652

2021 Revenue in Millions : 773

Growth (%) : -16

blank

09

Brand Name : Cozaar/Hyzaar

Hydrochlorothiazide

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Cozaar/Hyzaar

arrow
Medlab Asia & Asia Health
Not Confirmed

Hydrochlorothiazide

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 323

2021 Revenue in Millions : 357

Growth (%) : -10

blank

10

Brand Name : Cozaar/Hyzaar

Hydrochlorothiazide

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Cozaar/Hyzaar

arrow
Medlab Asia & Asia Health
Not Confirmed

Hydrochlorothiazide

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 281

2022 Revenue in Millions : 323

Growth (%) : -13

blank